saxagliptin news from FierceBiotech
News
FDA panel backs added risk review on diabetes drugs
A FDA advisory panel has voted 14-2 to recommend that the developers of diabetes drugs specifically demonstrate that their experimental therapies don't increase cardiovascular risks. And if as Read more...
DPP-4 inhibitors get spotlight at ADA meeting
Researchers are unveiling positive data at the American Diabetes Association's meeting for new DPP-4 inhibitors for diabetes. Takeda is the latest, demonstrating that its alogliptin can control blood Read more...
1. AstraZeneca and Bristol-Myers Squibb
Who: AstraZeneca With: Bristol-Myers Squibb What: $1.05 billion collaboration Summary: In an unusual partnership between drug giants, AstraZeneca agreed to pay Bristol-Myers Squibb $100 million up Read more...
Paid Research Reports
- Leading Drug Delivery Companies and Technologies: Competitive landscape, company profiles and technological developments
- Drug Repositioning Strategies - Serendipity by design
- eHealthInsight Series: Online Patient Recruitment Strategies - Optimizing the clinical trial process
- Pricing & Reimbursement - Seven Major Markets Update
- Innovative Clinical Trial Design and Management: Trends, success stories and impact upon R&D budgets